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tandard treatment for venous thromboembolism
Pulmonary embolism (PE) is a fatal complication of venous
hromboembolism (VTE). Several clinical situations are recognized
s risk factors for VTE including cancer, surgery, immobilization,
regnancy and postpartum, major trauma, use of oral contracep-
ives, and congenital or acquired coagulation disorders. In most
ases, PE develops as a consequence of deep vein thrombosis
DVT), which is a common complication after surgery, in partic-
lar, total knee or hip arthroplasty (TKA, THA). Since PE often
auses recurrent VTE and serious complications such as chronic
hromboembolic pulmonary hypertension, anticoagulation ther-
py should be recommended to prevent fatal PE and to minimize
he risk of developing recurrent VTE. Currently, standard treat-
ent for PE involves the overlapping intravenous or subcutaneous
dministration of low-molecular weight heparin (LMWH), unfrac-
ionated heparin (UFH), or fondaparinux with oral vitamin K
ntagonists (VKAs), which means actually warfarin. In acute phase
f PE, more aggressive treatment such as intravenous thromboly-
is or transcatheter thromboembolectomy would be required if the
atient’s hemodynamics are unstable. Although the optimal dura-
ion of anticoagulation therapy in the treatment of VTE remains
nclear, administration of LMWH,  UFT, or fondaparinux for at least
 days in the acute phase and the use of VKAs for 3 months or
ore in the chronic phase are recommended in the guidelines of the
uropean Society of Cardiology (ESC) [1] and the American College
f Chest Physicians (ACCP) [2].
lternatives to warfarin in case of ineffectiveness or
ntolerance of warfarin
Warfarin, the sole available VKA in Japan, is widely used for the
econdary prevention of VTE. As is well-known, warfarin has many
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Open accesclinical limitations such as multiple food and drug interactions,
slow onset and slow offset of its action, and narrow therapeutic
range to prevent thrombosis and minimize hemorrhagic com-
plications. Therefore, monitoring of international ratio (INR) of
prothrombin time is necessary to obtain the beneﬁcial antithrom-
botic effect of warfarin. However, it is often difﬁcult to maintain
the levels of INR within the optimal therapeutic range, resulting in
the ineffectiveness of warfarin. When unexpected clinical ﬁndings
such as recurrent or repetitive VTE develop under warfarin therapy
despite the levels of INR being within the optimal window, other
possibilities should be ruled out, i.e. warfarin dose may simply be
insufﬁcient for the patient, heparin-induced thrombocytopenia is
complicated by coadministration with heparin, or patients have any
underlying coagulation disorder such as protein C or S deﬁciency
and antiphospholipid antibody syndrome. Warfarin allergy, which
can be diagnosed by a drug-induced lymphocyte stimulation test,
can also become the reason for intolerance and the abandonment of
warfarin treatment. In these cases, alternatives to warfarin should
be considered. Although novel oral anticoagulants (NOACs), includ-
ing thrombin inhibitor dabigatran, factor Xa inhibitors rivaroxaban
and apixaban, are currently allowed for use only in patients with
nonvalvular atrial ﬁbrillation (NVAF) in Japan, the use of NOACs
could be chosen as a therapeutic option for patients with VTE
because NOACs have potential action for anticoagulation as well
as conventional anticoagulants (Fig. 1). Indeed, some NOACs have
been approved for VTE prophylaxis in Europe, Canada, the USA, and
other countries. Only in Japan, another factor Xa inhibitor edoxaban
has recently been approved for VTE prophylaxis after orthopedic
surgery with TKA or THA [3], but it has not yet been approved for
NVAF.
In the present case report [4], alternative use of rivaroxaban
was effective for the treatment of acute DVT and PE in a patient
with warfarin allergy. Since only rivaroxaban has the approval as a
single oral treatment option for acute symptomatic DVT [5] and
acute symptomatic PE [6] in western counties, the selection of
rivaroxaban would be appropriate as a result. However, accord-
ing to previous clinical trials, the efﬁcacy and safety of dabigatran
[7–11] and apixaban [12] are similar to those of rivaroxaban [5,6],
even though the inhibitory sites in the coagulation cascade between
factor Xa inhibitors and thrombin inhibitors are pharmacologically
different (Fig. 1). Therefore, any NOAC as an alternative to warfarin
can be considered in cases of ineffectiveness of or intolerance to
warfarin.
In addition, recent case reports demonstrated that NOACs could
also be substituted for ineffective warfarin in patients with NVAF,
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∗ Tel.: +81 42 371 2111; fax: +81 42 372 7379.ig. 1. The simpliﬁed coagulation cascade and inhibitory sites of anticoagulants.
MWH,  low-molecular weight heparin; UFH, unfractionated heparin; NOACs, novel
esulting in the resolution of left atrial appendage thrombus with
abigatran [13] or rivaroxaban [14].
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